Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 15/20 | 0.69 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.58 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.58 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.58 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.54 |
| ▸ | HTR7 | P34969 | 2/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | HTR1D | P28221 | 1/20 | 0.48 |
| ▸ | HTR1B | P28222 | 1/20 | 0.48 |
| ▸ | HTR1F | P30939 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
| ▸ | FNTA | P49354 | 1/20 | 0.47 |
| ▸ | FNTB | P49356 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3264614 | 0.87 | HTR6 (0.54) | HTR6TAAR1HDAC1HDAC10HDAC8 | |
| SCHEMBL3250179 | 0.86 | HTR6 (0.58) | HTR6TAAR1HDAC1HDAC10HDAC8 | |
| SCHEMBL3263430 | 0.85 | TAAR1 (0.56) | HTR6TAAR1HDAC1HDAC10HDAC8 | |
| SCHEMBL3251339 | 0.85 | HTR6 (0.52) | HTR6TAAR1HDAC1HDAC10HDAC8 | |
| SCHEMBL3257594 | 0.85 | HTR6 (0.60) | HTR6TAAR1HDAC1HDAC10HDAC8 | |
| SCHEMBL3256595 | 0.83 | HTR6 (0.74) | HTR6HTR7HTR1ADRD2HTR1D | |
| SCHEMBL3252416 | 0.82 | TAAR1 (0.52) | HTR6TAAR1HDAC1HDAC10HDAC8 | |
| SCHEMBL28811759 | 0.82 | HTR6 (0.59) | HTR6TAAR1CYP19A1FNTAFNTB | |
| SCHEMBL3253396 | 0.81 | TAAR1 (0.51) | HTR6TAAR1HDAC1HDAC10HDAC8 | |
| SCHEMBL3248620 | 0.81 | TAAR1 (0.51) | HTR6TAAR1HDAC1HDAC10HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1537113-B9 | ARYLALKYL INDOLES HAVING SEROTONIN RECEPTOR AFFINITY USEFUL AS THERAPEUTIC AGENTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SUVEN LIFE SCIENCES LTD (IN) | 2010-05-26 | — | — | EP | disclosed |
| EP-1537113-B1 | ARYLALKYL INDOLES HAVING SEROTONIN RECEPTOR AFFINITY USEFUL AS THERAPEUTIC AGENTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SUVEN LIFE SCIENCES LTD (IN) | 2009-10-07 | — | — | EP | disclosed |
| US-7297711-B2 | Arylalkyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them | SUVEN LIFE SCIENCES LIMITED (IN) | 2007-11-20 | — | — | US | disclosed |
| US-20050203103-A1 | Arylalkyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them | SUVEN LIFE SCIENCES LIMITED (IN) | 2005-09-15 | — | — | US | disclosed |
| CN-1662538-A | Arylalkyl indoles having sertonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them | SUVEN PHARMACEUTICALS LTD (IN) | 2005-08-31 | — | — | CN | disclosed |
| EP-1537113-A1 | ARYLALKYL INDOLES HAVING SEROTONIN RECEPTOR AFFINITY USEFUL AS THERAPEUTIC AGENTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Suven Pharmaceuticals Ltd. (IN) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004000845-A1 | ARYLALKYL INDOLES HAVING SERTONIN RECEPTOR AFFINITY USEFUL AS THERAPEUTIC AGENTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SUVEN LIFE SCIENCES LIMITED (IN) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203103-A1 | Arylalkyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them | TPH1, HTR1A, HTR7 | HTR6 9/4885TAAR1 39/4885HDAC1 3609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.